11/10/2021
Form 6-K - Statement of voting rights and shares forming the company's share capital
07/10/2021
Form 6-K - Nanobiotix to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
29/09/2021
Form 6-K - Nanobiotix announces Red Journal publication of preclinical data showing radioenhancer NBTXR3 may “reprogram” the tumor microenvironment to overcome anti-PD-1 resistance and evoke abscopal effect
10/09/2021
Form 6-K - Statement of Total Voting Rights and Shares Forming the Company's Share Capital as of August 31, 2021
09/09/2021
Form 6-K - Nanobiotix To Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09/09/2021
Form 6-K - Nanobiotix provides business update and reports financial results for the first half of 2021
08/09/2021
Form 6-K - Half-Year Financial Report
08/09/2021
Form 6-K - Exhibit 99.2: Agreement between LianBio and Nanobiotix
26/07/2021
Form 6K - Nanobiotix provides second quarter operational and financial update
07/07/2021
Form 6K - Nanobiotix announces initiation of new clinical study evaluating NBTXR3 in lung cancer
09/06/2021
Form 6K - Nanobiotix Virtual KOL Discussion
07/06/2021
Form 6-K - Nanobiotix reports new data for potential first-in-class radioenhancer NBTXR3 in combination with anti-PD-1 showing local or distant tumor regression in 76.9% of evaluable patients regardless of prior anti-PD-1 exposure
07/06/2021
Form 6-K - Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to support global expansion
27/05/2021
Form 6-K - Nanobiotix to participate in fireside chat at the Jefferies Virtual Healthcare Conference
26/05/2021
Form 6-K - Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
20/05/2021
Form 6-K - Nanobiotix announces updated results from priority pathways in head and neck cancer and immunotherapy for potential first-in-class radioenhancer NBTXR3 at 2021 annual meeting of the American Society for Clinical Oncology
19/05/2021
Form 6-K - Nanobiotix To Present At The UBS Global Healthcare Virtual Conference
19/05/2021
Form 6-K - Nanobiotix Partners With Lianbio To Develop And Commercialize Potential First-In-Class Radioenhancer NBTXR3 Across Tumor Types And Therapeutic Combinations In China And Other Asian Markets
03/05/2021
Form 6-K - Nanobiotix announces first quarter operational and financial updates
29/04/2021
Form 6-K - Nanobiotix to present four posters including updates from priority head and neck cancer and immunotherapy development pathways
29/04/2021
Form 6-K - Attendees list
15/04/2021
FORM 6-K - Resolution text
12/04/2021
FORM 6-K - Nanobiotix Combined Shareholders Meeting To Be Held April 28, 2021
08/04/2021
FORM 20-F - Annual report
08/04/2021
FORM 6-K - Nanobiotix Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
17/03/2021
FORM 6-K - Nanobiotix Reports Full Year 2020 Financial Results And Highlights Operational Progress
05/03/2021
FORM 6-K - Nanobiotix and Pharmaengine mutually agree to conclude collaboration
02/03/2021
FORM 6-K - Preclinical data presented at AACR virtual special conference
26/02/2021
FORM 6-K - Nanobiotix announces 2020 Q4 and annual revenues
28/01/2021
FORM 6-K - Nanobiotix announces first patient injected with NBTXR3 in esophageal cancer
25/01/2021
FORM 6-K - Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline
15/01/2021
FORM 6-K - Nanobiotix announces positive first results for novel NBTXR3 in rectal cancer study
